RE: Conference call Liver tox data20 Feb 2019 01:59
Hi Ian,
Good summary and thanks for posting.
Given the minor difference, especially on the pooled data and the fact that nobody died or had any liver failure/complications, its almost unthinkable that the fda would not approve iclaprim.
I'm sure there is some further detail thats not in the public domain but would it change anything? It does not sound like it can be anything adverse or not consistent to the performance against vanc with the public domain stuff and given that iclaprim performs better than vanc and linz in all other outcomes...seems very unusual.
You never know, this could be very straight forward. Provide the additional data because we need the finite detail on record to allow approval.
No wonder they are baffled by the crl but then again, the fda sets the criteria and they want to be sure so we will just have to wait and see.
Surely, its not in their thinking to not approve it because there's not a big enough benefit in terms of efficacy against vanc?
I wonder if theres something left field within the fda thinking like the approval of iclaprim could speed up the resistance against vanc?
Or, do they view iclaprim as an important drug but its just not needed at this point and they will approve it at a later stage when they best think it will serve its most useful purpose?